Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study

被引：0

作者：

Bressler, B. ^{[1
]}

Peyrin-Biroulet, L. ^{[2
,3
]}

Afif, W. ^{[4
]}

Samaan, M. A. ^{[5
]}

Wei, S. C. ^{[6
]}

Yarandi, S. ^{[7
]}

Germinaro, M.

Mistry, P. ^{[8
]}

Han, C. ^{[9
]}

Allegretti, J. R. ^{[10
]}

Lichtenstein, G. R. ^{[11
]}

机构：

[1] Univ British Columbia, Gastroenterol, Vancouver, BC, Canada

[2] Univ Lorraine, Inserm, NGERE, F-54000 Nancy, France

[3] Grp Hosp Prive Ambroise Pare Hartmann Paris IBD Ct, Gastroenterol, Nancy, France

[4] McGill Univ Hlth Care, Div Gastroenterol, Montreal, PQ, Canada

[5] Guys & St Thomas NHS Fdn Trust, Inflammatory Bowel Dis Unit, London, England

[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[7] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[8] Janssen Res & Dev LLC, Biostat, Spring House, PA USA

[9] Janssen Res & Dev LLC, Patient Reported Outcomes, Spring House, PA USA

[10] Harvard Med Sch, Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[11] Univ Penn, Gastroenterol, Philadelphia, PA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1343

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1169

引用

页码：i2133 / i2135

页数：3

共 50 条

[21] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
Sands, Bruce E.
Rubin, David T.
Lichtenstein, Gary
Shipitofsky, Nicole
Huang, Kuan-Hsiang
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
DuVall, Aaron
Cao, Qian
Allegretti, Jessica R.
Feagan, Brian G.
Peyrin-Biroulet, Laurent
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Bressler, Brian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S526 - S527
[22] Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
Rubin, D.
Panes, J.
Feagan, B.
Yarandi, S.
Huang, K. H.
Germinaro, M.
Han, C.
Miao, Y.
Zhang, H.
Qiu, Y.
Klopocka, M.
Duvall, G.
Lichtenstein, G.
Hisamatsu, T.
Bressler, B.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1816 - I1817
[23] Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Rubin, David T.
Panes, Julian
Feagan, Brian G.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Qiu, Yun
Klopocka, Maria
Duvall, George
Lichtenstein, Gary R.
Hisamatsu, Tadakazu
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S677 - S677
[24] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Watanabe, Mamoru
Motoya, Satoshi
Watanabe, Kenji
Ogata, Haruhiko
Kanai, Takanori
Matsui, Toshiyuki
Suzuki, Yasuo
Shikamura, Mitsuhiro
Igeta, Masataka
Oda, Kazunori
Hori, Tetsuharu
Araki, Takahiro
Hibi, Toshifumi
GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
[25] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Lichtenstein, Gary R.
Dignass, Axel
Rubin, David T.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Miao, Ye
Zhang, Hongyan
Kierkus, Jaroslaw
Seidler, Ursula
Maemoto, Atsuo
Allegretti, Jessica R.
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
[26] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Allegretti, Jessica R.
Peyrin-Biroulet, Laurent
Feagan, Brian G.
Bressler, Brian
Lichtenstein, Gary R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Jiang, Lingjing
Zhang, Hongyan
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Sands, Bruce E.
Rubin, David T.
GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
[27] Health-Related Quality of Life in Chinese Patients with Mild and Moderately Active Ulcerative Colitis
Zheng, Kai
Zhang, Shengsheng
Wang, Chuijie
Zhao, Wenxia
Shen, Hong
PLOS ONE, 2015, 10 (04):
[28] Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
Panes, Julian
Vermeire, Severine
Lindsay, James O.
Sands, Bruce E.
Su, Chinyu
Friedman, Gary
Zhang, Haiying
Yarlas, Aaron
Bayliss, Martha
Maher, Stephen
Cappelleri, Joseph C.
Bushmakin, Andrew G.
Rubin, David T.
JOURNAL OF CROHNS & COLITIS, 2018, 12 (02): : 145 - 156
[29] Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
Panes, J.
Loftus, E. V., Jr.
Armuzzi, A.
Siegmund, B.
Sands, B. E.
Boland, B. S.
Kalabic, J.
Lai, J. H.
Sharma, D.
Remple, V.
Gonzalez, Y. Sanchez
Lindsay, J. O.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1585 - I1586
[30] Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn's disease: Phase 3 GRAVITI study
Sands, B.
Danese, S.
Cao, Q.
Steinwurz, F.
Kierkus, J.
Han, C.
Olurinde, M.
Yang, Z.
Merrall, E.
Terry, N. A.
Hart, A.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2102 - i2104

← 1 2 3 4 5 →